(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 353.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Renovorx's revenue in 2025 is $240,000.On average, 2 Wall Street analysts forecast RNXT's revenue for 2025 to be $58,698,432, with the lowest RNXT revenue forecast at $45,715,290, and the highest RNXT revenue forecast at $71,681,575. On average, 2 Wall Street analysts forecast RNXT's revenue for 2026 to be $188,164,134, with the lowest RNXT revenue forecast at $164,575,044, and the highest RNXT revenue forecast at $211,753,223.
In 2027, RNXT is forecast to generate $1,015,610,883 in revenue, with the lowest revenue forecast at $1,015,610,883 and the highest revenue forecast at $1,015,610,883.